Factors associated with pre-treatment HIV RNA: application for the use of abacavir and rilpivirine as the first-line regimen for HIV-infected patients in resource-limited settings

BACKGROUND: Abacavir and rilpivirine are alternative antiretroviral drugs for treatment-naïve HIV-infected patients. However, both drugs are only recommended for the patients who have pre-treatment HIV RNA <100,000 copies/mL. In resource-limited settings, pre-treatment HIV RNA is not routinely pe...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:AIDS Res Ther
Main Authors: Kiertiburanakul, Sasisopin, Boettiger, David, Ng, Oon Tek, Van Kinh, Nguyen, Merati, Tuti Parwati, Avihingsanon, Anchalee, Wong, Wing-Wai, Lee, Man Po, Chaiwarith, Romanee, Kamarulzaman, Adeeba, Kantipong, Pacharee, Zhang, Fujie, Choi, Jun Yong, Kumarasamy, Nagalingeswaran, Ditangco, Rossana, Cuong, Do Duy, Oka, Shinichi, Sim, Benedict Lim Heng, Ratanasuwan, Winai, Ly, Penh Sun, Yunihastuti, Evy, Pujari, Sanjay, Ross, Jeremy L., Law, Matthew, Sungkanuparph, Somnuek
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2017
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5420083/
https://ncbi.nlm.nih.gov/pubmed/28484509
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12981-017-0151-1
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados